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| INTRODUCTION
Food allergy is an increasingly common condition in Western countries as well as Asia, affecting~6-8% of children and~4% of adults. 1, 2 It is caused by inappropriate T cell-driven immune responses to harmless food components of milk, eggs, peanuts, tree nuts, seafood, shellfish, soya, wheat (the "big eight") and other foods.
Food allergy often co-occurs with other atopic diseases such as allergic rhinitis and conjunctivitis, eczema and allergic asthma and is believed to result mechanistically from the breakdown of the T cell suppressive mechanisms conferred by oral immune tolerance. Symptoms of food allergy usually occur with a fast onset (from seconds to 1 hour) and include rashes, hives, swelling and itching of parts or the whole face, wheezing, diarrhoea, nausea and, in severe cases, anaphylaxis. The mainstay of treatment is the strict avoidance of food allergens; accidental intake requires epinephrine injections in severe and antihistamines and steroids in mild cases. The benefits of allergen immunotherapy for food allergies are currently unclear, and the procedures are thus not (yet) recommended.
The hygiene 3 and disappearing microbiota 4 hypotheses postulate that the reduced exposure to environmental and pathogenic microbes early in life and/or the loss of ancestral indigenous microbes colonizing various niches of the human body contribute to an increased allergy risk. Both hypotheses have served to explain the dramatic increase in the prevalence of food allergy in Western countries. The paradigmatic example of a microbe that is increasingly lost from human populations is H. pylori. Chronic infection with this gastric colonizer on the one hand represents an important risk factor for the development of gastritis, ulcers and gastric cancer 5, 6 but on the other hand appears to confer protection against oesophageal disorders such as gastro-oesophageal reflux disease and oesophageal cancer, as well as asthma, allergy and inflammatory bowel diseases. 7, 8 Whereas the inverse association of H. pylori with allergic asthma, rhinitis and eczema is well supported by large epidemiological studies and meta-analyses, 9-12 the effects of H. pylori positivity on the risk of developing food allergy are controversial.
Few reports are available, and the existing studies suffer from small sample sizes, heterogeneous populations and non-standardized methodologies. 13 Several studies have found a positive association of H. pylori, especially of strains harbouring the virulence factor CagA, with food allergy in children 14, 15 or adults. 16 Other studies have found no association, 17 or a negative association. 12 The latter study reported both a decreased seroprevalence of H. pylori in food allergy patients relative to controls (33% vs 40% as determined by urea breath test and serology) as well as a reduced production of allergic mediators (such as eosinophilic cationic protein and mast cell tryptase) in H. pylori-positive relative to H. pylori-negative food allergy patients. 12 Mechanistically, positive associations with food allergy were explained by a breakdown of the epithelial barrier to food allergens due to the chronic inflammation of the H. pyloriinfected gastric mucosa, whereas negative associations were attributed to the immunomodulatory activity of H. pylori on the activation and polarization of T cell responses.
We have previously examined the role of H. pylori in various experimental models of allergic asthma and have consistently detected a strong protective effect, especially of neonatal exposure to the bacteria, on the development of allergic asthma in response to various allergens. [18] [19] [20] as described previously. 22 The dosage of extract and VacA was 
| Allergen-specific ELISAs
For OVA-specific IgG1 ELISA, high-affinity plates were coated with 10 lg OVA in carbonate-bicarbonate coating buffer (pH 9.6) overnight at 4°C. After washing and blocking with 2% BSA in PBS, serum samples were diluted in 1% BSA/PBS and added for 2 hours at 37°C. After further washing, the plates were incubated for 1 hour at 37°C with HRP-coupled anti-mouse IgG1 (eBioscience 18-4015-82).
Wells were washed again before adding HRP substrate and measuring absorbance in a Spectromax plate reader. OVA-specific IgE was measured using the same procedure as described for IgG1, except that HRP-coupled anti-mouse IgE (GeneTex GTX77227) was used for detection. For PE-specific IgE ELISA, high-affinity plates were coated with 500 lg PE overnight as described above. After washing and blocking with 5% gelatine in PBS at 37°C for 1 hour, serum samples diluted in 2% BSA/PBS were added to the plate for 2 hours at 37°C. After further washing, the plates were incubated with anti- Briefly, Chelex-100 beads (Bio-Rad, Cressier, Switzerland) were added after the lysis step and incubated at 95°C for 15 minutes in a shaker. Chelex-100 beads were spun down, and the supernatant was transferred to a fresh tube. After addition of an adjusted amount of 100% ethanol, the following purification steps were performed according to the manufacturer's protocol. Genomic DNA was converted with bisulphite using the EZ DNA Methylation Kit (Zymo Research, Benley Cir Tustin, California, USA) according to the manufacturer's instructions. The Treg-specific demethylated region (TSDR) was amplified by PCR and analysed by pyrosequencing on a PSQ96MA (Qiagen, Hilden, Germany) as described recently. 23 Primers for sequencing were 
| Statistical analysis
GraphPad Prism 6 was used for all statistical analyses. In all graphs, each symbol represents an individual animal and horizontal lines indicate medians. The Kruskal-Wallis test followed by Dunn's multiple comparisons test was used throughout. Stars are used to indicate the level of significance according to the P-value: *P < .05, **P < .01, ***P < .001, ****P < .0001. Figure 1B-D, Fig. S1A,B) . The re-stimulation of splenic single-cell preparations with OVA revealed a clearly elevated production of IL-5 and IL-13 relative to control groups that had not been sensitized (but challenged) or had never been exposed to OVA ( Figure 1E,F) . In contrast, mice that were infected with H. pylori or had received H. pylori whole-cell extract were assigned significantly lower anaphylaxis scores, exhibited reduced serum levels of OVAspecific IgG1 and produced lower amounts of splenic Th2 cytokines upon re-stimulation ( Figure 1B-F) ; the assessment of serum MCPT-1 levels confirmed these trends for the extract treatment, but not for the live infection, and serum IgE levels were not reduced by either extract treatment or live infection (Fig. S1A,B) . Overall, the results indicate that H. pylori infection and extract treatment efficiently reduce anaphylaxis symptoms and most other hallmarks of ovalbumin-specific allergy; the effects on anaphylaxis scores in particular, the most relevant readout from a clinical perspective, are strong and robust.
| Food allergy symptoms induced by peanut extract are reduced by Helicobacter pylori infection and treatment with H. pylori extract or the H. pylori immunomodulator VacA
We next sought to determine whether these results could be corroborated in additional models of food allergy. As proteins contained in peanuts are among the most common food allergens in Western societies, we opted for peanut-specific sensitization and challenge.
Mice received four intragastric weekly doses of cholera toxinadjuvanted peanut extract (PE) for the purpose of sensitization, followed by intragastric challenge with PE on 4 consecutive days F I G U R E 1 OVA-induced food allergy is ameliorated by neonatal Helicobacter pylori infection or weekly extract treatment. (A) Schematic of OVA-induced food allergy and H. pylori-specific interventions. Mice were sensitized twice intraperitoneally (i.p.) with 50 lg of alum-adjuvanted OVA and orally challenged 4 wks after the first sensitization on 4 consecutive days with 60 mg OVA (s/c; positive controls). Negative control animals were challenged but not sensitized, or neither sensitized nor challenged. One group of mice was neonatally infected on day 6 and 7 after birth with the H. pylori strain PMSS1 (inf), and another group was treated weekly by oral gavage with 100-200 lg (adjusted to body weight) whole-cell H. pylori extract starting on day 6 or 7 after birth (extr p. Horizontal lines indicate medians; the Kruskal-Wallis test followed by Dunn's multiple comparisons test was used throughout for the calculation of P-values. *P < .05, **P < .01, ***P < .001 beginning 1 week after the last sensitization (Figure 2A ). Neonatally infected mice and mice treated with either H. pylori extract or the purified H. pylori immunomodulator VacA were sensitized and challenged alongside a group of positive controls that received no intervention whatsoever. The food allergy symptoms elicited by intragastric sensitization and challenge with peanut extract were relatively mild and comparable to symptoms induced with OVA ( Figure 2B-D) . Similar to the OVA model, regular treatment with extract or the purified immunomodulator VacA effectively reduced the anaphylaxis scores, but failed to affect peanut-specific serum IgE levels; live infection had no significant effect on any of the parameters but showed a trend towards lower anaphylaxis scores (Figure 2B,C) . MCPT serum levels were modestly reduced by all three interventions ( Figure 2D ), albeit not significantly. In summary, we KYBURZ ET AL.
| 1335 observe in two complementary food allergy models that H. pyloribased prophylactic interventions reduce clinically relevant symptoms of food allergy and modulate immunologic correlates of the disease.
| Severe anaphylaxis induced by peanut extract is alleviated by Helicobacter pylori
Both above-described models of food allergy produce relatively mild symptoms. Mice rarely develop systemic symptoms such as decreased activity or effects on respiration rates. To mimic more severe anaphylactic reactions, which can be life-threatening in peanut-allergic children, we devised a model that produced significantly higher anaphylaxis scores, accompanied by higher serum MCPT levels and stronger cytokine production by re-stimulated splenocytes relative to the other two models. In this model, mice were sensitized orally by four CT-adjuvanted doses of peanut extract followed by two intraperitoneal challenges with the same extract (Figure 3A) . Most mice of the positive control group were assigned anaphylaxis scores of three (defined as laboured respiration and cyanosis around the mouth and tail and/or periods of motionless for more than 1 minutes, lying prone on stomach) or four (slight or no activity after prodding/whisker stimuli or tremors and convulsion; Figure 3B ,C) already after the first challenge dose. Anaphylaxis scores were strongly reduced by treatment with VacA, but not so much by the other examined interventions ( Figure 3B) ; moreover, the Th2 cytokine production of re-stimulated splenocytes ( Figure 3D ,E) and MCPT and IgE levels measured in serum showed only modest trends (Fig. S2A,B) . Finally, we switched to a fourth model of food allergy, this time using particularly anaphylaxis-sensitive C3H mice. 24 These mice exhibited anaphylaxis scores of up to three upon oral sensitization and challenge, and thus indeed proved to be more susceptible to peanut extract than C57BL/6 mice also in our hands (Fig. S3A-C) . Regular H. pylori extract treatment had modest, but not statistically significant, effects on anaphylaxis scores, serum MCPT levels and spleen weights ( Fig. S3B-E ). Treatment with VacA had similar effects, but too few mice were analysed to draw definitive conclusions ( Fig. S3B-E) . In summary, the severe anaphylaxis induced by the intraperitoneal administration of allergen to sensitized C57BL/6 mice, or the oral challenge of C3H mice, can be reduced somewhat by prior infection with H. pylori, or the regular exposure to H. pylori extract or VacA.
F I G U R E 2 Amelioration of allergic symptoms in an oral challenge peanut allergy model upon Helicobacter pylori-specific treatments. (A) Schematic of PE-induced food allergy and H. pylori interventions. Mice were sensitized four times by oral gavage (p.o.) with 2 mg of peanut extract (PE) adjuvanted with 20 lg cholera toxin (CT), followed 4 wks later by oral challenges on 4 consecutive days with 60 mg OVA (positive controls). Negative control animals were challenged but not sensitized, or neither sensitized nor challenged. One group of mice was neonatally infected on days 6 and 7 after birth with the H. pylori strain PMSS1 (inf), and another group was treated weekly by oral gavage with 100-200 lg (adjusted to body weight) whole-cell H. pylori extract starting on days 6 or 7 after birth (extr p.o.). A final group received once-weekly increasing doses (adjusted to body weight) of 5-20 lg purified VacA (VacA i.p.) starting on days 6 or 7 after birth. (B) Cumulative anaphylaxis score assigned upon challenge (sum of three scores). (C,D) Serum PE-specific IgE and MCPT1 levels, as determined by ELISA. In B-D, each symbol represents one mouse. Graphs show pooled data from 4 (B), 3 (C) and 2 (D) experiments. Horizontal lines indicate medians; the KruskalWallis test followed by Dunn's multiple comparisons test was used throughout for the calculation of P-values.*P < .05, ****P < .0001 F I G U R E 3 Systemically induced peanut food allergy is reduced upon neonatal Helicobacter pylori infection or weekly treatment with extract or VacA. (A) Schematic of PE-induced food allergy and H. pylori interventions. Mice were sensitized four times by oral gavage (p.o.) with 2 mg of peanut extract (PE) adjuvanted with 20 lg cholera toxin (CT), followed 1 wk later by two i.p. challenges (with a 3-d interval) with 1 mg PE (positive controls). Negative control animals were challenged but not sensitized, or neither sensitized nor challenged. One group of mice was neonatally infected on day 6 and 7 after birth with the H. pylori strain PMSS1 (inf), and another group was treated weekly by oral gavage or i.p. with whole-cell H. pylori extract starting on day 6 or 7 after birth (extr p. demethylation has functional consequences with respect to Treg expansion and regulatory cytokine expression. We conclude from these data that epigenetic marks leading to stable expression of FoxP3, and to the definitive lineage commitment of Tregs, reflect the suppressive effects of H. pylori-specific treatments on food allergy in the models described above. the effects on clinical symptoms were associated with protective effects on systemic parameters of food allergy, such as mast cell protease levels in serum and allergen-specific IgG1 levels in some but not all models. The effects of H. pylori on food allergy were not as impressive as its beneficial effects in models of allergic asthma in which neonatal exposure to the bacteria essentially reduces parameters of airway inflammation, airway hyperresponsiveness and goblet cell metaplasia to almost background levels. [18] [19] [20] The stronger effects in the asthma models may have to do with the so-called gut-lung axis, the idea of a special connection between the mucosal immune systems of the two organs that has been put forward to explain the effects of (deliberate or pathogenic alterations of) the gut microbiota on lung diseases. 29 We were able to link the protection against the airway hyper-reactivity, inflammation, eosinophilia and excessive mucus production that are hallmarks of allergic asthma to the strong suppressive activity of H. pylori-induced Tregs. 
| DISCUSSION

